#1
#1 out of 1
business15h ago
Key facts: AstraZeneca Q1 $15.29B; Datroway Delayed; Licenses PTX-299
- AstraZeneca reported Q1 2026 revenue of $15.29 billion, with product sales at $14.39 billion.
- The company reaffirmed its 2026 guidance despite the late-stage trial delays.
- Two Datroway late-stage lung cancer trials were delayed to 2027, affecting near-term pipeline timing.
- AZN bought an exclusive global license for PTX-299, paying $25 million upfront with potential milestones and royalties.
- The PTX-299 deal includes potential milestones and royalties possibly exceeding $500 million.
- Analysts largely favor AstraZeneca with a mix of buy and strong buy ratings; the 12‑month target sits above the last close.
- TradingView notes AZN will report earnings in the European results round, with no figures provided yet.
- AZN's oncology segment remains a major revenue contributor, comprising about 44% of total revenue.
- AZN's core operating profit rose about 12% in the first quarter.
- The AZN-PTX-299 deal could become a significant growth driver if milestones and royalties materialize.
Vote 0